April 22, 2014
Eli Lilly Japan has initiated a PIII study of the selective phosphodiesterase type 5 (PDE5) inhibitor tadalafil in the country for the treatment of Duchenne muscular dystrophy (DMD), which occurs primarily in boys. The clinical trial will be conducted in...read more